History of Research on Tumor Angiogenesis

The book explores the pivotal hypothesis by J. Folkman in 1971 that tumor growth relies on angiogenesis, leading to significant advancements in cancer treatment. It highlights the approval of the first angiogenesis inhibitor by the FDA in 2004 and compiles relevant literature to illustrate the evolution of antiangiogenic therapies in oncology. The focus is on the historical context and the impact of targeting blood vessel formation in combating tumors.